EPA:ABNX • FR0012616852
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABIONYX PHARMA SA (ABNX.PA).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.252M 678.07% | 4.64M -11.65% | 4.551M -1.92% | 4.641M 1.98% | 4.641M | 14.841M 219.78% | 39.429M 165.68% | |
| EBITDA YoY % growth | -3.974M 31.87% | -3.259M 17.99% | -4.33M -32.86% | -10.251M -136.74% | -19.176M -87.06% | -12.036M 37.23% | -39.454M -227.80% | |
| EBIT YoY % growth | -4.109M 30.96% | -3.412M 16.96% | -4.465M -30.86% | -10.506M -135.30% | -19.431M -84.95% | -12.291M 36.75% | -39.454M -221.00% | |
| Operating Margin | -78.24% | -73.53% | -98.11% | -226.37% | -418.68% | -82.82% | -100.06% | |
| EPS YoY % growth | N/A -25.00% | N/A 10.00% | N/A 11.11% | -0.22 -34.37% | -0.46 -111.63% | -0.30 36.26% | -0.89 -199.69% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
8 analysts have analysed ABNX.PA and the average price target is 10.71 EUR. This implies a price increase of 228.02% is expected in the next year compared to the current price of 3.265.
The expected long term growth rate for ABIONYX PHARMA SA (ABNX.PA) is 46.79%.